Mr. Philip Renaud reports

KANE BIOTECH TO HOST COMMERCIAL UPDATE WEBCAST ON SEPTEMBER 16

Kane Biotech Inc. will host a virtual commercial update on Wednesday, Sept. 16, 2026, at 11 a.m. Eastern Time.

The one-hour webcast will provide shareholders, prospective investors and other stakeholders with an update on Kane's focus on building a clinically credible and commercially disciplined wound-care business, including the company's strategy to convert revyve into meaningful, recurring revenue through sustained clinical adoption, productive commercial channels and repeatable product sales.

The details of the webcast are as follows:

Date:  Wednesday, Sept. 16, 2026

Time:  11 a.m. Eastern Time

Duration:  approximately 60 minutes, including a question-and-answer session

Format:  virtual presentation followed by a question-and-answer session

Investors, shareholders and other stakeholders are encouraged to register in advance to participate in the live webcast and Q&A (question-and-answer_ session. A replay of the webcast will be made available at the company website following the event.

Philip Renaud, chair of Kane's board of directors, will participate in the presentation.

Dr. John C. Lantis, site chief of surgery at Mount Sinai West Hospital and professor of surgery at the Icahn School of Medicine at Mount Sinai, will also participate in the presentation. Dr. Lantis is an experienced vascular surgeon and wound-care investigator who has served as principal investigator on more than 70 multicentre and single-centre chronic-wound and vascular-surgery trials. His presentation will provide an expert clinical perspective on chronic wounds, wound biofilms and the practical requirements for bringing new wound-care technologies into clinical use, including his experience with revyve Antimicrobial Wound Spray in venous leg ulcers.

Dr. Robert Huizinga, interim chief executive officer of Kane Biotech, will present an operational and commercial update. The presentation will address the work undertaken to strengthen Kane's commercial foundation, advance its clinical evidence strategy, expand routes to market, and focus the company on converting commercial access into repeatable product adoption and revenue.

"Over the past year, Kane has changed how it approaches governance, evidence generation and commercialization," said Philip Renaud, chair of the board. "This webcast gives us an opportunity to speak directly to shareholders and other stakeholders about that work, put the company's progress into clear clinical and commercial context, and outline the execution priorities that will guide Kane's next phase."

Kane's revyve portfolio currently includes United States Food and Drug Administration 510(k) cleared revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser. The wound gel and wound gel spray are also approved by Health Canada. Kane is ISO 13485:2016 certified under the Medical Device Single Audit Program.

"Product clearance and scientific evidence are essential, but they are not the same as commercial success," said Dr. Huizinga. "Our priority is to translate Kane's biofilm expertise and the revyve platform into sustained clinical adoption, productive commercial channels and demonstrable revenue traction. We intend to discuss both the progress made and the work that remains."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved.

We seek Safe Harbor.